A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO ASSESS PHARMACOKINETICS AND COMPARE THE EFFICACY, SAFETY, AND TOLERABILITY OF P1101 VS ANAGRELIDE AS SECOND LINE THERAPY FOR ESSENTIAL THROMBOCYTHEMIA (SURPASS ET): THE CORE STUDY AND ITS EXTENSION STUDY

Registry ID

P1101ET

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PHARMAESSENTIA CORPORATION

Start date

2021-11-29

Last update

2021-07-02

Conditions

• ESSENTIAL THROMBOCYTHEMIA

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BOMEDEMSTAT (MK-3543) VERSUS HYDROXYUREA IN CYTOREDUCTIVE THERAPY NAÏVE ESSENTIAL THROMBOCYTHEMIA PARTICIPANTS
• A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BOMEDEMSTAT (MK-3543/IMG-7289) VERSUS BEST AVAILABLE THERAPY (BAT) IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA WHO HAVE AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
• A SINGLE-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF ROPEGINTERFERON ALFA-2B-AJFT (P1101) IN ADULT PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

View on source registry